Osiris Therapeutics (OTCMKTS: OSIR) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.
Insider and Institutional Ownership
0.3% of Osiris Therapeutics shares are owned by institutional investors. Comparatively, 22.7% of Anavex Life Sciences shares are owned by institutional investors. 44.6% of Osiris Therapeutics shares are owned by company insiders. Comparatively, 11.6% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Osiris Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
This table compares Osiris Therapeutics and Anavex Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anavex Life Sciences||N/A||-70.10%||-63.39%|
This is a breakdown of recent recommendations for Osiris Therapeutics and Anavex Life Sciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anavex Life Sciences||0||0||2||0||3.00|
Anavex Life Sciences has a consensus target price of $14.50, indicating a potential upside of 355.97%. Given Anavex Life Sciences’ higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Osiris Therapeutics.
Earnings & Valuation
This table compares Osiris Therapeutics and Anavex Life Sciences’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Osiris Therapeutics||$59.87 million||3.35||-$1.78 million||N/A||N/A|
|Anavex Life Sciences||N/A||N/A||-$13.46 million||($0.33)||-9.64|
Osiris Therapeutics has higher revenue and earnings than Anavex Life Sciences.
Osiris Therapeutics beats Anavex Life Sciences on 5 of the 9 factors compared between the two stocks.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.
About Anavex Life Sciences
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.
Receive News & Ratings for Osiris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.